Chugai Pharmaceutical Co., Ltd. (CHGCF)
42.57
+7.31
(+20.72%)
USD |
OTCM |
Sep 17, 16:00
Chugai Pharmaceutical Enterprise Value : 64.23B for Sept. 17, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 17, 2026 | 64.23B |
| September 16, 2026 | 52.21B |
| September 15, 2026 | 61.94B |
| September 14, 2026 | 65.33B |
| September 11, 2026 | 64.53B |
| September 10, 2026 | 59.76B |
| September 09, 2026 | 62.26B |
| September 08, 2026 | 66.14B |
| September 04, 2026 | 65.49B |
| September 03, 2026 | 66.58B |
| September 02, 2026 | 62.63B |
| September 01, 2026 | 62.31B |
| August 31, 2026 | 67.01B |
| August 28, 2026 | 67.25B |
| August 27, 2026 | 66.22B |
| August 26, 2026 | 64.74B |
| August 25, 2026 | 63.96B |
| August 24, 2026 | 68.04B |
| August 21, 2026 | 63.34B |
| August 20, 2026 | 65.08B |
| August 19, 2026 | 64.65B |
| August 18, 2026 | 62.82B |
| August 17, 2026 | 67.88B |
| August 14, 2026 | 65.29B |
| August 13, 2026 | 65.89B |
| Date | Value |
|---|---|
| August 12, 2026 | 66.50B |
| August 11, 2026 | 65.01B |
| August 10, 2026 | 67.41B |
| August 07, 2026 | 64.75B |
| August 06, 2026 | 65.67B |
| August 05, 2026 | 62.24B |
| August 04, 2026 | 66.04B |
| August 03, 2026 | 63.77B |
| July 31, 2026 | 65.23B |
| July 30, 2026 | 70.81B |
| July 29, 2026 | 63.26B |
| July 28, 2026 | 63.01B |
| July 27, 2026 | 65.64B |
| July 24, 2026 | 73.74B |
| July 23, 2026 | 62.76B |
| July 22, 2026 | 66.00B |
| July 21, 2026 | 66.53B |
| July 20, 2026 | 67.58B |
| July 17, 2026 | 70.61B |
| July 16, 2026 | 67.09B |
| July 15, 2026 | 63.02B |
| July 14, 2026 | 64.71B |
| July 13, 2026 | 66.79B |
| July 10, 2026 | 67.42B |
| July 09, 2026 | 66.10B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 87.77B |
| Daiichi Sankyo Co., Ltd. | 33.45B |
| Eisai Co., Ltd. | 8.852B |
| Santen Pharmaceutical Co., Ltd. | 3.378B |
| Ono Pharmaceutical Co., Ltd. | 6.585B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 730.02M |
| Revenue (Quarterly) | 2.144B |
| Total Expenses (Quarterly) | 1.414B |
| EPS Diluted (Quarterly) | 0.4436 |
| Gross Profit Margin (Quarterly) | 69.49% |
| Profit Margin (Quarterly) | 34.06% |
| Earnings Yield | 4.36% |
| Operating Earnings Yield | 6.27% |
| Normalized Earnings Yield | 4.564 |